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The terminal phase of programmed cell death, 
removal of apoptotic cells, is a critical homeo-
static function involved in an array of diverse 
cellular processes ranging from embryonic de-
velopment and tissue remodeling to resolution 
of infl  ammation (1, 2). Controlled phagocytic 
engulfment of apoptotic cells suppresses infl  am-
mation by limiting cytolysis and necrosis (2–4). 
Multiple receptors are implicated in macro-
phage clearance of apoptotic cells including 
CD36, a prototypic member of the class B scav-
enger receptor family (5–11). In vitro studies 
suggest a role for the CD36 scavenger receptor 
in the recognition of apoptotic cells because 
both endogenous (e.g., macrophages and den-
dritic cells) and ectopic (e.g., melanoma cells 
and fi  broblasts) expression of CD36 on the sur-
face of cells confers phagocytic activity for en-
gulfment of apoptotic cells (8, 12, 13). Despite 
the many demonstrations of CD36 recognition 
of apoptotic cells using in vitro model systems, 
direct demonstration of CD36 involvement in 
apoptotic cell clearance in vivo is lacking.
CD36 is widely expressed on the surface 
of  multiple cell types including macrophages, 
adipocytes, platelets, microvascular endothelial 
cells, and specialized epithelial cells. A heavily 
glycosylated mutiligand receptor belonging to 
the class B scavenger receptor group, CD36 is 
reported to mediate uptake of oxidized low 
density lipoprotein (oxLDL), as well as to play a 
role in diverse cellular processes including foam 
cell formation, fatty acid transport, engulfment 
and removal of senescent cells, suppression of 
angiogenesis, and cell–matrix interactions (7, 
8, 10, 14–17). Multiple distinct binding sites 
on CD36 are reported to facilitate its broad li-
gand specifi  city and functions. CD36 interac-
tion with oxLDL is supported via recognition 
by the N-terminal region of the receptor (18–20). 
CD36-dependent uptake of oxLDL has been 
shown to be critical to cholesterol accumula-
tion and subsequent foam cell formation, ac-
tivities that likely contribute to the observed 
involvement of CD36 in mouse models of 
  atherogenesis (21, 22).
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The phagocytosis of apoptotic cells within an organism is a critical terminal physiological 
process in programmed cell death. Evidence suggests that apoptotic cell engulfment and 
removal by macrophages is facilitated by phosphatidylserine (PS) displayed at the exofacial 
surface of the plasma membrane; however, neither the macrophage receptors responsible 
for PS recognition, nor characterization of the PS molecular species potentially involved, 
have been clearly defi  ned. We show that the class B scavenger receptor CD36 plays an 
essential role in macrophage clearance of apoptotic cells in vivo. Further, macrophage 
recognition of apoptotic cells via CD36 is shown to occur via interactions with membrane-
associated oxidized PS (oxPS) and, to a lesser extent, oxidized phosphatidylcholine, but not 
nonoxidized PS molecular species. Mass spectrometry analyses of oxPS species identify 
structures of candidate ligands for CD36 in apoptotic membranes that may facilitate 
macrophage recognition. Collectively, these results identify oxPS–CD36 interactions on 
macrophages as potential participants in a broad range of physiologic processes where 
macrophage-mediated engulfment of apoptotic cells is involved.
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Abbreviations used: CMFDA, 
5-chloromethylfl  uorescein 
  diacetate; Di-I, 1,1’-
dioctadecyl-3,3,3′,3′-
tetramethlyindocarbocyanine 
perchlorate; IRES, internal 
ribosome entry signal; MPM, 
mouse peritoneal macrophage; 
MPO, myeloperoxidase; m/z, 
mass-to-charge ratio; oxLDL, 
oxidized low density lipopro-
tein; oxPC, oxidized PC; 
  oxPCCD36, oxidized PC species 
possessing an sn-2 acyl group 
that incorporates a terminal 
γ-hydroxy(or oxo)-α,β-
unsaturated carbonyl; oxPS, 
oxidized PS; oxPSCD36, oxidized 
PS species possessing an sn-2 
acyl group that incorporates a 
terminal γ-hydroxy(or oxo)-
α,β-unsaturated carbonyl; 
PAPS, 1-palmitoyl-2-
arachidenoyl-sn-glycero-3-
phosphoserine; PC, 
phosphatidylcholine; PLPS, 
1-palmitoyl-2-lineoyl-sn-
glycero-3-phosphoserine; 
POPC, 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine; 
POPS, 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoserine; PS, 
phosphatidylserine; PSR, PS 
receptor; SUV, small unilamel-
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Until recently, the precise chemical structures of oxidized 
species in the LDL particle recognized by CD36 were un-
known. Recent studies using a combination of cell binding 
  assays, mass spectrometry, and both analytical and synthetic 
chemistry successfully isolated and structurally defi  ned a novel 
oxidized phosphatidylcholine (oxPC) species possessing an sn-2 
acyl group that incorporates a terminal γ-hydroxy(or oxo)-
α,β-unsaturated carbonyl (oxPCCD36) that serves as high affi   n-
ity ligands for CD36 via the oxLDL site (23, 24). A conserved 
structural motif within oxidized choline glycerophospholipids 
that promotes high affi   nity CD36 binding was defi  ned; namely, 
a phospholipid with an oxidatively truncated sn-2 acyl group 
that incorporates a terminal γ-hydroxy(or oxo)-α,β-  unsaturated 
carbonyl. Only trace levels (a few molecules per particle) of the 
oxPCCD36 were required to support CD36 binding, and the en-
richment of these ligands was shown in multiple oxLDL prepa-
rations and within atherosclerotic lesions (23, 24).
The mechanisms through which CD36 recognizes apop-
totic cells have not been clearly defi  ned. Early studies identi-
fi  ed an interaction between CD36 and phosphatidylserine 
(PS)-containing membranes (8, 9, 25), suggesting that PS 
externalization during the apoptotic process may serve as a 
trigger for conferring macrophage phagocytosis via scavenger 
receptor recognition. Studies using recombinant expression 
systems in conjunction with competitive synthetic peptides 
and antibodies have identifi  ed a putative PS binding site on 
the receptor (26) distinct from the oxLDL binding domain 
that facilitates CD36 interactions with PC-containing mem-
branes or liposomes (18–20).
Detailed investigation of both the receptors involved and 
the nature of the PS ligands in macrophage–apoptotic cell 
interactions has remained largely unexplored. Although it is 
generally assumed that native (nonoxidized) PS is the ligand 
recognized on apoptotic cells by macrophages, a recent study 
suggests the potential involvement of oxidized PS (oxPS) as 
well (27). A role for PS–CD36 interactions in recognition of 
apoptotic cells has been reported using in vitro model systems; 
however, direct demonstration of a role for CD36 in apop-
totic cell clearance in vivo is lacking. Because the common 
structural motif within the oxPCCD36 ligands previously 
identifi  ed was localized to the esterifi  ed sn-2 fatty acid chain 
(23, 24), we hypothesized that other phospholipid analogues, 
such as those from oxPS (i.e., an oxPS species possessing 
an sn-2 acyl group that incorporates a terminal γ-hydroxy(or 
oxo)-α,β-unsaturated carbonyl [oxPSCD36]), may be able to 
function as high affi   nity ligands for CD36, facilitating recog-
nition between the apoptotic cell membrane and CD36 on 
the macrophage cell surface. This seemed especially plausible 
because previous reports of CD36-mediated phagocytosis of 
apoptotic cells via PS failed to consider that oxidation of 
lipids may be important, and hence, no measures to prevent 
lipid oxidation were used (8, 9, 25, 26). In this paper, using 
CD36 KO mice and a wound healing model, we show a 
direct role for CD36 in apoptotic cell clearance. Moreover, 
using a combination of both direct binding and competition 
studies, along with mass spectrometry characterizations, we 
now show that oxPS species, but not nonoxidized PS, serve 
as preferred ligands within apoptotic cells for CD36-mediated 
phagocytosis by macrophages.
RESULTS
Apoptotic cells accumulate in CD36 KO mice wounds 
relative to CD36 WT
In full thickness 6-mm punch biopsy wound healing exper-
iments conducted on CD36 KO and WT mice, we noted a 
two- to threefold increase in apoptotic cell numbers in 
wounds from CD36 KO mice at multiple time points, con-
sistent with delayed clearance of apoptotic cells in the CD36 
mice (Fig. 1). In vitro control studies using primary CD36-
expressing macrophages isolated from background-matched 
WT and CD36 KO mice demonstrated no diff  erences in 
apoptosis rates to apoptogenic triggers such as serum depri-
vation, staurosporin, or Fas ligand (unpublished data). In 
addition, both morphometric and histological analyses 
revealed no observable diff  erences in either the overall rate 
of wound closure or leukocyte (monocyte and neutrophil) 
recruitment between CD36 KO and WT animals over a 9-d 
period after wound injury (unpublished data). Collectively, 
these results demonstrate that CD36 KO mice have im-
paired ability to effi     ciently clear apoptotic cells from an 
infl  ammatory setting.
CD36-specifi  c binding and uptake of PS-containing vesicles 
is mediated by oxidized, not nonoxidized, PS species, 
as monitored by quantitative fl  ow cytometry
The nature of the ligands on apoptotic cell membranes 
recognized by macrophage CD36 has not been clearly 
defi  ned. Although previous data suggest a role for PS, recent 
experimental studies with CD36–oxLDL interactions 
showed a requirement for oxidized choline glycerophospho-
lipids. We therefore hypothesized that oxPS, and not PS, 
might play a role in macrophage CD36 recognition of 
apoptotic membranes.
Before investigating the ability of CD36 to specifi  cally 
bind to oxPS, we sought to develop a tractable system with 
which we could simultaneously monitor CD36 expression, 
manipulate vesicle, liposome, or lipoprotein lipid composi-
tion, and also quantify particle binding. A bicistronic 
CD36,GFP reporter plasmid containing an internal ribosome 
entry signal (IRES) was constructed for simultaneous expres-
sion of full-length WT human CD36 and GFP. Use of this 
construct results in GFP expression in constant molar ratio 
with intact native human CD36 within transfected cells, 
permitting cellular mean GFP fl  uorescence to be used as a 
quantitative measure proportional to CD36 expression. As 
illustrated in Fig. 2 a, fl  ow cytometry analyses of transiently 
transfected leukemia (K562) cells with the bicistronic 
construct resulted in CD36 surface expression at levels that 
increase proportionately with increasing cellular GFP 
fl  uorescence. Similar results were seen using alternative cell 
types (Jurkat T cells, COS-7 fi  broblasts, human embryonic 
kidney cells, or THP-1 human monocyte/macrophage like JEM VOL. 203, November 27, 2006  2615
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line; unpublished data). Confi  rmation that the recombinant 
human CD36 was localized to the cell surface in these sys-
tems was achieved by fl  uorescent microscopy studies using 
anti-CD36 antibody on fi  xed, nonpermeabilized cells. Dem-
onstration that surface CD36 was functional in the transfected 
cells was achieved by showing that cells only bound appre-
ciable levels of 1,1’-dioctadecyl-3,3,3′,3′-tetramethlyindo-
carbocyanine perchlorate (Di-I)–labeled oxLDL in the 
presence of CD36 (Fig. 2 b). Two-color fl  ow  cytometry 
analyses with the described system (GFP fl  uorescence moni-
tored for measure proportional to cell CD36 expression and 
Di-I fl  uorophore for labeled lipoproteins or liposomes) per-
mitted simultaneous monitoring of CD36-specifi  c increases 
in particle binding across a range of CD36 surface expression 
levels. This is illustrated in Fig. 2 c, where K562 cells were 
transiently transfected with either GFP alone (control) or the 
CD36,GFP bicistronic construct, incubated with Di-I–
  labeled oxLDL, and analyzed by two-color fl  ow cytometry. 
A dramatic increase in specifi  c binding of oxLDL in propor-
tion with increasing CD36 expression is noted (Fig. 2, d and e).
We next examined the CD36 binding activity of various 
molecular species of PS versus oxPS using a fl  uorescent vesicle 
system in which presentation of the various PS species was 
maintained relatively uniform by incorporation of only a 
  minor mole percent of PS within a lamellar phase–preferring 
carrier lipid, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line (POPC), under the experimental conditions (i.e., tem  perature) 
used. Small unilamellar vesicle (SUV) POPC with 1 mol% 
Di-I and 20 mol% 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoserine (POPS), 1-palmitoyl-2-lineoyl-sn-glycero-3-
phosphoserine (PLPS), or 1-palmitoyl-2-arachidenoyl-sn-
glycero-3-phosphoserine (PAPS; either as native form or after 
oxidation by the myeloperoxidase [MPO]–H2O2–NO2
− sys-
tem) were generated by extrusion and incubated with CD36-
expressing (CD36,GFP bicistronic) versus control-expressing 
(GFP only) cells. Remarkably, only oxPS-containing vesicles 
demonstrated enhanced CD36-specifi  c binding, with the ex-
tent of binding proportional to cellular expression of CD36 
(Fig. 3). PS species possessing the oxidation-susceptible sn-2 
linoleic or arachidenic acids were readily converted into 
CD36 binding ligands by oxidation, whereas PS possessing 
the relatively nonoxidizable sn-2 fatty acid oleic acid did not 
promote CD36 binding despite exposure to oxidation sys-
tems (Fig. 3). These results are consistent with mass spectrom-
etry studies that demonstrated no signifi  cant modifi  cation of 
the parent lipid (POPS; unpublished data) but signifi  cant for-
mation of multiple oxPS species (Table I) from PLPS- and 
PAPS-containing vesicles after oxidant exposure.
Macrophages use CD36 to recognize bilayers containing 
oxidized PS rather than nonoxidized PS species
By using the fl  ow cytometry–based assay developed to moni-
tor vesicle binding, we conclude that oxPS, as opposed to 
PS, in a membrane bilayer serves as a preferred ligand for 
CD36 across multiple orders of magnitude of CD36 surface 
expression on the target transfected cell. Because recombi-
nant   systems that expressed CD36 have the potential to 
  inaccurately refl  ect endogenous CD36–oxPS binding inter-
actions, we performed additional studies to determine 
whether our observations in transfected cos-7 and K562 cells 
were representative of endogenous CD36 binding behavior 
within macrophages. Mouse peritoneal macrophages (MPMs) 
from WT versus CD36 KO mice were incubated with Di-I–
labeled SUVs containing low mole percent PS versus oxPS 
species, and both immunolocalization of macrophage CD36 
and vesicle binding were concomitantly monitored. Marked 
increases in oxPS binding to WT versus CD36 KO perito-
neal macrophages were noted (Fig. 4, a and b), consistent with 
CD36 serving as the predominant oxPS   receptor expressed in 
mouse macrophages. oxPS binding occurred exclusively in 
Figure 1.  Increased apoptotic cell accumulation in CD36 KO mice 
wounds compared with WT. (a) Punch biopsy wounds from WT and 
CD36 KO mice were excised on days 8, 9, and 12 and stained (green) for 
apoptotic cells using a fl  uorescein DNA fragmentation kit (see Materials 
and methods). Skin is autofl  uorescent (red). Bar, 500 μm (b) Quantitation 
of apoptotic cell numbers from WT and CD36 KO wounds (day 8 after 
wound). Results represent the mean ± SD for six independent animals 
per group.2616  PHAGOCYTOSIS OF APOPTOTIC CELLS VIA CD36 REQUIRES OXIDIZED PS | Greenberg et al.
Figure 2.  Development of two-color fl  ow cytometry–based bind-
ing assay permitting concomitant quantifi  cation of CD36 surface 
expression level and ligand binding. (a) K562 (chronic myelogenous 
leukemia) cells were transfected with plasmids encoding empty vector 
(control), only human CD36, only GFP, or both CD36 and GFP using the 
bicistronic (IRES) vector as described in Materials and methods. Cells were 
cultured overnight, and cell surface CD36 (CD36-mAb conjugated to phy-
coerythrin) and GFP fl  uorescence were simultaneously analyzed by two-
color fl  ow cytometry. Note that the bicistronic plasmid expresses cell 
surface CD36 receptor in a dose-dependent manner as a function of GFP 
fl  uorescence. (b) Cos-7 cells were transfected with DNA plasmids encod-
ing either GFP only or both CD36 and GFP proteins using the bicistronic 
vector. Cells were then incubated at 4°C in the absence versus presence of 
oxLDL labeled with the lipophilic dye Di-I), washed, and visualized, as 
described in Materials and methods. Note that a high degree of Di-I fl  uo-
rescence (oxLDL binding) is only observed in cells transfected with CD36 
and that the cells demonstrating Di-I fl  uorescence (oxLDL binding) have 
cellular staining patterns similar to those observed for GFP within the 
CD36 + GFP bicistronic transfected cells (images D, E, and F). For com-
parison, only background Di-I fl  uorescence is seen in cells transfected 
with GFP only (images A, B, and C). Bar, 50 μm (c) K562 cells transfected 
with plasmids expressing CD36,GFP (bicistronic) or GFP alone were cul-
tured overnight and incubated with 40 μg/ml oxidized (via the MPO-
NO2
−–H2O2 system) LDL labeled with the lipophilic dye Di-I at 4°C for 
30–60 min. After extensive washing to remove unbound oxLDL, CD36 
expression (a function of GFP fl  uorescence) and oxLDL binding (red JEM VOL. 203, November 27, 2006  2617
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WT and not CD36 KO macrophages. Both WT and CD36 
KO macrophages also demonstrated low but detectable lev-
els of binding to nonoxidized PS (Fig. 5 b).
Vesicles possessing oxidized PS, but not nonoxidized PS, 
inhibit phagocytosis of apoptotic cells 
in a CD36-dependent manner
To explore the potential role of CD36–oxPS interactions in 
macrophage engulfment of apoptotic cells, we examined the 
capacity of SUVs possessing PS versus oxPS species to inter-
fere with macrophage phagocytosis of apoptotic cells. Con-
fl  uent monolayers of both WT and CD36 KO MPMs were 
overlaid with viable versus apoptotic HL60 cells. After incu-
bation, nonadherent/nonphagocytosed cells were removed 
by vigorous washing, and engulfment of apoptotic cells was 
quantifi  ed by in situ peroxidase staining. Fig. 5 a illustrates 
the assay, with visualization of WT MPMs phagocytosing 
control (1) or apoptotic (2) peroxidase-containing HL60 cells.
To further explore the role of oxPS in macrophage engulf-
ment of apoptotic cells via CD36, parallel studies were per-
formed in the presence of small unilamellar POPC vesicles 
containing either low mole percent incorporation of   either PS 
or oxPS as potential competitors of apoptotic cell phagocytosis. 
As noted in Fig. 5 b, SUVs possessing oxPS were signifi  cantly 
more effi   cient than those with PS at inhibiting apoptotic cell 
phagocytosis by WT macrophages. No competitive inhibitory 
eff  ect of oxPS-containing vesicles was noted in CD36 KO 
macrophages. CD36 KO macrophages demonstrated en-
hanced inhibition in apoptotic cell phagocytosis with vesicles 
containing nonoxidized PS species, consistent with possible 
adaptive up-regulation of an   alternative receptor in the CD36-
null mice that recognizes native PS but not oxPS forms.
Because macrophages have multiple potential alternative re-
ceptors that could participate in apoptotic cell recognition in 
vivo (one or more of which appear to be up-regulated in the 
CD36 KO MPMs), we sought to perform parallel studies ex-
amining the involvement of CD36–oxPS interactions in a cell 
type with low endogenous background levels of PS and oxPS 
recognition. For these studies we selected COS-7 fi  broblasts be-
cause transfection of these cells with human CD36 has previ-
ously been shown to confer professional phagocytic function to 
this otherwise nonphagocytic cell (12), and binding studies with 
the native cells demonstrate low background levels with SUVs 
containing either PS or oxPS species. In the absence of a com-
petitor, COS-7 cells transfected with human CD36 (but not 
vector control) demonstrated enhanced phagocytic capacity to-
ward multiple diff  erent apoptotic cells (e.g., data for apoptotic 
HL60 human monocyte/macrophage cells and fl  uorescently 
labeled apoptotic Jurkat T cells are shown in Fig. 5 (c and d, re-
spectively). Co-incubation of vesicles containing oxPS species, 
but not nonoxidized PS, with apoptotic cells markedly inhibited 
phagocytosis by the CD36-transfected Cos-7 cells.
Vesicles possessing oxPS more effi  ciently inhibit 
macrophage-mediated phagocytosis of apoptotic cells 
than vesicles containing oxPC
Because both the previously identifi  ed family of oxPCCD36 
  ligands and the putative oxPSCD36 ligands may share common 
fl  uorescence) were analyzed simultaneously by two-color fl  ow cytometry. 
A representative fl  ow cytometry dot plot is shown. Note that oxLDL binds 
to CD36-expressing cells in a dose-dependent fashion (i.e., with increas-
ing CD36 expression there is a corresponding increase in oxLDL binding). 
(d) The mean oxLDL-Di-I fl  uorescence is plotted against the relative CD36 
expression levels as monitored by the mean GFP fl  uorescence intensity 
from triplicate binding experiments shown in panel a. (e) LDL binding is 
shown for the single CD36 expression level (as measured by the GFP fl  uo-
rescence intensity interval), indicated by the dashed-line rectangle in d. 
Results represent the mean ± SD for three independent experiments.
Figure 3.  Recombinant CD36 preferentially binds to oxPS-
  containing lipid vesicles compared with nonoxidized PS-containing ves-
icles. (a) K562 cells were transfected with plasmids expressing GFP alone 
(control) or CD36,GFP (bicistronic), cultured overnight, and incubated at 
4°C for 1 h with phospholipid vesicles (prepared by extrusion of 80 mol% 
POPC + 20 mol% of PS [PLPS or PAPS and the lipophilic dye Di-I at 
1 mol%]). Before incubation, vesicles were either oxidized (via the MPO-
NO2
−–H2O2 system) or untreated. After extensive washing to remove un-
bound lipid vesicles, CD36 expression (proportional to GFP fl  uorescence) 
and the corresponding amount of fl  uorescent lipid ligand bound (Di-I 
fl  uorescence) were analyzed simultaneously by two-color fl  ow cytometry 
as in Fig. 2. Panel a shows the mean fl  uorescence values for triplicate 
experiments. Open symbols represent oxidized PS liposomes, closed sym-
bols represent untreated (nonoxidized) PS liposomes. (b) Fluorescent lipo-
some binding shown as a function of the single GFP fl  uorescence 
intensity interval indicated by the dashed-line rectangle in panel a. Data 
are expressed as the mean ± SD of triplicate samples and are representa-
tive of at least three separate experiments.2618  PHAGOCYTOSIS OF APOPTOTIC CELLS VIA CD36 REQUIRES OXIDIZED PS | Greenberg et al.
recognition epitopes in the truncated, oxidized sn-2 fatty 
acid chain, we were interested to test whether oxPC lipo-
somes could compete with oxPS liposomes for binding 
to CD36-expressing cells. Using the fl  uorescent binding as-
say of Di-I–labeled oxPS vesicles incubated with CD36-
transfected K562 cells, we added a 10-fold excess (bulk lipid 
concentration) of unlabeled oxPS- or oxPC-containing 
SUVs (same mole percent incorporation of oxPS vs. oxPC) 
to compete for CD36-specifi  c binding. As shown in Fig. 6 a, 
although excess nonlabeled oxPS SUVs markedly attenu-
ated Di-I–oxPS SUV binding to CD36-expressing cells, a 
comparable molar excess of oxPC-possessing SUVs had 
only a modest inhibitory eff  ect. At a single surface expres-
sion level of CD36 (Fig. 6 b), note that Di-I–labeled oxPS 
SUVs demonstrate only modest ( 20%) reductions in CD36-
specifi   c binding in the presence of a 10-fold excess of 
oxPC SUVs but at least 90% reduction in binding in the 
presence of comparable incubations with excess unlabeled 
oxPS SUVs.
To further examine the relative contribution of oxPS 
versus oxPC in macrophage recognition of apoptotic cells, 
MPMs from WT mice were incubated with apoptotic cells 
in the absence versus presence of similar SUV preparations 
comprised of POPC only or POPC carrier plus 20 mol% 
of the indicated nonoxidized versus oxPC and oxPS molecu-
lar species (Fig. 6 c). Most notable was that all SUVs com-
prised of only nonoxidized phospholipids failed to inhibit 
MPM phagocytosis of apoptotic cells. Further, although 
  addition of oxidized 1-palmitoyl-2-arachidenoyl-sn-glycero-3-
phosphocholine–containing vesicles (but not 1-palmitoyl-2-
arachidenoyl-sn-glycero-3-phosphocholine) partially inhibited 
macrophage phagocytosis of apoptotic cells, the eff  ect was 
only modest. In contrast, SUVs containing oxPS but not 
nonoxidized PS molecular species (1,2-dipalmitoyl-sn-
glycero-3-phosphoserine, POPS, or PLPS) markedly inhib-
ited macrophage engulfment of apoptotic cells. Collectively, 
these data support a major role for macrophage-mediated 
phagocytosis of apoptotic cells via CD36 interaction with 
apoptotic membrane oxPS species. They also suggest that 
oxPC species can participate, albeit to a lesser degree, in 
apoptotic cell recognition via CD36.
Enrichment of oxidized PS species, but not nonoxidized PS, 
within cellular membranes of nonapoptotic cells promotes 
enhanced CD36-dependent phagocytosis by macrophages
To independently confi  rm that enrichment of oxPS within 
membranes confers CD36-dependent recognition, we 
performed a series of studies where oxPS versus PS was 
integrated into the plasma membranes of viable cells, and 
their phagocytosis by WT versus CD36 KO macrophages 
was quantifi  ed. For these studies, enrichment of plasma 
membrane lipids was achieved as described in Materials 
and methods, with incorporation of either POPC carrier 
alone or with addition of low mole percent (16 mol%) in-
corporation of either PAPS or oxidized PAPS species. 
Both the oxPS- and PS-enriched HL60 cells showed simi-
lar enhancement in annexin V staining compared with 
control (POPC carrier lipid) treated cells, suggesting simi-
lar levels of phosphatidyserine exposure (nonoxidized and 
oxidized) at the plasma membrane (Fig. 7 a). Enriching the 
Table I.  Parent ([M-H]−) and characteristic daughter ions (MS2 and MS3) of candidate CD36 ligands from oxidized PAPS and PLPS
PL-PS oxidation products
m/z MS2 MS3 Structure of sn-2 side chain Abbreviations
650.3 563.3 409/391/307/255/171/153 9-oxononanoic acid ON-PS
666.3 579.3 409/391/323/255/187/153 Azeleic acid A-PS
704.3 617.3 409/391/361/255/225/153 9,12-dioxododec-10-enoic acid KODA-PS
706.3 619.3 409/391/363/255/227/153 9-hydroxy-12-oxodedec-10-enoic acid HODA-PS
720.3 633.3 409/391/377/255/241/153 9-oxo-11-carboxyundec-6-enoic acid KDdiA-PS
722.3 635.3 409/391/379/255/243/153 9-hydroxy-11-carboxyundec-6-enoic acid HDdiA-PS
758.3 671.3 Linoleic acid  PL-PS
PA-PS oxidation products
m/z MS2 MS3 Structure of sn-2 side chain Abbreviations
594.3 507.3 409/391/255/251/153/115 5-oxovaleric acid OV-PS
610.3 523.3 409/391/267/255/153/131 Glutaric acid G-PS
648.3 561.3 409/391/305/255/169/153 5,8-dioxooct-6-enoic acid KOOA-PS
650.3 563.3 409/391/307/255/153 5-hydroxy-8-oxooct-6-enoic acid HOOA-PS
664.3 577.3 409/391/321/255/184/153 5-oxo-7-carboxyhept-6-enoic acid KOdiA-PS
666.3 579.3 409/391/323/255/187/153 5-hydroxy-7-carboxyhept-6-enoic acid HOdiA-PS
782.3 695.3 Arachidonic acid PA-PS
PAPS and PLPS were individually oxidized and analyzed by HPLC with on-line electrospray ionization mass spectrometry on an iontrap instrument using MSn mode. Parent 
and characteristic MS2 and MS3 daughter ions (for sn-2 oxfatty acid) are shown. Ions in the MS2 spectrum that are produced after neutral loss (m/z = 87) of aziridine-2-
carboxylic acid (Fig. 8) from the precursor parent ions were optimized and used as the precursor for MS3 experiments. The MS3 ions of the corresponding sn-2 oxidized fatty 
acids previously identifi  ed as CD36 ligands within oxPC species (references 23, 24) were isolated and fragmented. The structure and observed ions of the sn-2 chain of oxPS 
are shown. These corresponded to the previously identifi  ed sn-2 side chains on oxPC that serve as CD36 ligands.JEM VOL. 203, November 27, 2006  2619
ARTICLE
plasma membranes of viable (nonapoptotic) HL60 cells 
with oxPS markedly increased their phagocytosis by 
WT (CD36-expressing) MPMs, whereas no increase was 
noted with nonoxidized PS (Fig. 7 b). Interestingly, in 
contrast to WT macrophages, plasma membrane integra-
tion of nonoxidized PS resulted in more effi   cient binding 
and phagocytosis by CD36 KO MPMs (Fig. 7 c), again 
suggesting an apparent adaptive up-regulation of an alter-
native receptor for PS (nonoxidized forms only) in the 
CD36-null MPMs.
Mass spectrometry analysis of oxPS species suggests 
possible candidate ligands for CD36 in apoptotic cell 
membranes in vivo
Previously, we determined that a novel family of oxPC spe-
cies with enhanced CD36 binding activity formed in vivo 
(i.e., oxPC carrying an oxidatively truncated sn-2 acyl group 
with a terminal γ-hydroxy(or oxo)-α,β-unsaturated car-
bonyl) (23, 24). We were therefore interested to determine 
whether structural analogues of these CD36 ligands contain-
ing a PS headgroup are formed during apoptosis and PS oxi-
dation and might thus mediate CD36-dependent recognition 
of apoptotic cell membranes. We performed extensive char-
acterization of PAPS- and PLPS-derived oxidation products 
from synthetic precursor lipids (PAPS and PLPS) and apop-
totic cell membranes using multiple mass spectrometric ap-
proaches (including MSn) to determine if the anticipated 
oxPS analogues were formed.
Initially, oxPS species were generated and characterized 
by taking SUVs comprised of relatively oxidant-resistant car-
rier lamellar phase phospholipid (POPC) and trace levels 
(10–20 mol%) of either PAPS or PLPS and exposing them 
to a physiological oxidation system (MPO–H2O2–NO2
− sys-
tem) as described in Materials and methods. The resultant 
lipids were fractionated by reverse phase HPLC and exam-
ined on-line by electrospray ionization mass spectrometry 
(MSn mode) using an ion-trap instrument. A previous study 
(28) showed that PS species undergo characteristic fragmen-
tation patterns under negative ion electrospray ionization 
conditions (Fig. 8). Our analyses confi  rmed this. We used 
this information to initially identify candidate oxPS species 
by monitoring for ions that demonstrated neutral loss of aziri-
dine-2-carboxylic acid daughter (MS2) ions with characteris-
tic loss of 87 amu (Fig. 8 and Table I). Comparisons with the 
calculated theoretical mass of expected oxPS species gener-
ated reveal that besides the oxygenated long chain species, 
products with oxidatively truncated sn-2 fatty acids were also 
observed in the spectra. Among them, the molecular ions of 
sn-2 oxidized fatty acids from CD36 oxPC analogue ligands 
were also present (Table I). To confi  rm this, ions in MS2 
spectra that are produced after neutral loss of aziridine-2-
carboxylic acid from the precursor ions (parent oxPS) were 
collisionally dissociated, and MS3 ions were identifi  ed. 
Both individual corresponding synthetic oxPCCD36 (23, 
24), as well as theoretical ions and the fragmentation pat-
tern of sn-2 chains of the CD36 ligands, were calculated in 
parallel and compared with the ions directly monitored in 
oxPS MS3 spectra (Table I). The observation of the ex-
pected ions of sn-2 side chains in the MS3 spectrum pro-
vides additional evidence for the presence of the indicated 
specifi  c oxPS (Table I), the structural analogues of previ-
ously reported oxPCCD36 ligands (23, 24). From this we 
conclude that oxPSCD36 lipid ligands, structural and chemi-
cal analogues of oxPCCD36, were generated upon oxida-
tion of PAPS and PLPS and may thus potentially serve as 
recognition ligands for CD36-mediated phagocytosis of 
apoptotic cells.
Figure 4.  oxPS ligands show higher affi  nity for CD36 in vivo than PS. 
(a) Thioglycollate-elicited MPMs from CD36 WT and CD36 KO mice were 
incubated with Di-I–labeled oxPS- or PS-containing POPC vesicles pre-
pared as in Fig. 3. The extent of direct vesicle binding was visualized by 
fl  uorescent microscopy of the Di-I fl  uorophore and counterstained with 
anti–mouse CD36 antibody followed by goat anti–mouse IgA secondary 
antibody conjugated to fl  uorescein isothiocyanate (shown in anti-CD36 
column). Bar, 50 μm (b) The relative amounts of lipid binding were deter-
mined by quantifying the surface Di-I fl  uorescence from the micrograph 
in Fig. 4 a using ImagePro software. Results represent the mean ± SD of 
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To confi  rm formation of oxPS species in apoptotic cell 
membranes, such as those possessing an oxidatively truncated 
sn-2 acyl group with a terminal γ-hydroxy(or oxo)-α,β-
unsaturated carbonyl, a series of experiments were performed 
with membrane extracts. Recovered lipids were analyzed by 
LC/ESI/MS/MS analyses, and specifi   c oxPS species were 
identifi  ed by their characteristic retention times and mass-to-
charge ratio (m/z) of parent/daughter ion transitions using 
multiple reaction monitoring mode, as described in Materials 
and methods. In separate parallel analyses, the structure of the 
sn-2 oxidized fatty acid on the indicated oxPS species was 
further confi  rmed using MSn mode. Multiple specifi  c oxPS 
species possessing mass spectral characteristics indicative of 
oxPS harboring oxidatively truncated sn-2 fatty acids (Fig. 9) 
analogous to oxPC species previously shown to serve as CD36 
ligands were identifi  ed, suggesting that these structurally de-
fi  ned oxPS species may serve as potential CD36 ligands on 
apoptotic cells.
D  I  S  C  U  S  S  I  O  N 
This paper demonstrates a key role for CD36 in recognition 
of apoptotic cells in vivo. Further, macrophage recognition 
of apoptotic cells via the scavenger receptor CD36 is shown 
to occur virtually exclusively through interactions with 
oxPS, and to a lesser extent oxPC, but not nonoxidized PS, 
molecular species. The mass spectrometry studies performed 
also demonstrate the presence of potential candidate struc-
tures of specifi  c oxidized PS species within apoptotic cell 
membranes that may serve as ligands for the scavenger 
receptor CD36, based on their structural homology to re-
cently defi  ned oxPC molecular species possessing a high af-
fi   nity recognition motif for CD36 interaction (23, 24). 
Current dogma proposes that the initial triggering event for 
macrophage phagocytic recognition of apoptotic cells is the 
fl  ipping of PS to the exofacial surface, enabling scavenger 
receptors to engage and facilitate macrophage engulfment 
of the apoptotic cell. The present results suggest that 
an oxidative event may also be a prerequisite to macrophage 
phagocytosis of apoptotic cells via scavenger receptor CD36–
PS interactions. Whether such an oxidative event occurs 
within apoptotic cell membrane lipids before or after PS fl  ips 
to the exofacial surface after exposure to an apoptogenic 
stimulus remains unknown. Further, given the multiple 
Figure 5.  Co-incubation with oxPS vesicles competitively inhibits 
CD36-dependent phagocytosis of apoptotic cells. Phagocytosis assay 
of (a, 1) 106 untreated and (a, 2) 106 UV-irradiated apoptotic (as moni-
tored by DNA laddering assay and annexin V staining) HL60 cells overlaid 
onto 105 CD36 WT MPMs and incubated for 1 h at 37°C, followed by ex-
tensive washing with PBS to remove noningested and unbound apoptotic 
cells. Cells were stained with dimethylbenzidine (o-dianisidine), as de-
scribed in Materials and methods, to reveal bound and phagocytosed HL60 
cells that appear brownish-yellow in color. Bar, 50 μm (b) UV-irradiated 
HL60 cells were combined with lipid vesicles and overlaid onto CD36 WT 
or KO MPMs and incubated for 1 h at 37°C. After extensive washing, 
bound and ingested HL60 cells were revealed by in situ peroxidase 
(dimethylbenzidine) staining. (left) Total number of macrophage-associated 
(bound or ingested) HL60 cells in the presence of POPC vesicles contain-
ing 20 mol% PS or oxPS compared with no lipid vesicle co-incubation. 
(right) Percent inhibition of apoptotic HL60 cell association with MPMs 
conferred by oxPS- versus 20 mol% PS-containing POPC liposomes, as 
determined by ([number of untreated control cells − number of PS or 
oxPS–co-incubated cells]/number of untreated control cells) × 100. Note 
that POPC vesicles containing oxPS competitively inhibit the binding of 
apoptotic HL60 cells to CD36 WT MPMs compared with CD36 KO MPMs. 
(c) A similar experiment to that in b, with apoptotic HL60 cells overlaid 
onto CD36- or vector-transfected (control) Cos-7 cells (used as the 
phagocytic cell) and incubated with POPC vesicles containing either 20 
mol% PS or oxPS. (d) A similar experiment conducted with UV-irradiated 
apoptotic Jurkat T cells fl  uorescently labeled with CellTracker Green 
CMFDA as a marker for phagocytized cells, overlaid onto CD36- or vector-
transfected (control) Cos-7 cells and co-incubated with the indicated PS- 
versus oxPS-containing vesicle. *, P < 0.02 versus control.JEM VOL. 203, November 27, 2006  2621
ARTICLE
alternative receptors involved in apoptotic cell clearance and 
their varied expression levels within diff  erent tissues and con-
ditions, the relative contribution of oxPS–CD36 interactions 
to apoptotic cell clearance mechanisms in vivo is not clear. It 
seems reasonable to speculate that CD36–oxPS interactions 
may play a more prominent role at sites where lipid peroxi-
dation is enhanced, such as during infl  ammation.
A critical role for oxPS species in apoptotic cell recognition 
by macrophage CD36 is supported by multiple independent 
lines of evidence. We monitored oxPS liposome binding as a 
function of cell surface CD36 levels using a novel fl  uores-
cence-based assay and observed that liposomes containing 
oxPS, but not nonoxidized PS, preferentially bind to CD36-
transfected cells. Complementary studies using WT and 
CD36 KO MPMs confi  rm a requirement for oxidation of 
PS for cell binding and phagocytosis via endogenously ex-
pressed CD36 in macrophages. Further, incorporation of 
oxPS, but not PS, into viable nonapoptotic cell membranes 
was shown to confer CD36 binding activity and the capacity 
to be phagocytosed by CD36-bearing cells. Studies using multi-
ple distinct cells and apoptotic triggers confi  rm a critical role 
for oxPS versus PS as recognition ligands for CD36-mediated 
phagocytosis. Finally, using multiple mass spectrometry–based 
approaches, we show that oxPS species possessing a structur-
ally conserved CD36 recognition motif—an sn-2 acyl group 
that incorporates a terminal γ-hydroxy(or oxo)-α,β-unsatu-
rated carbonyl—are formed within apoptotic membranes 
and may thus play a role in CD36-dependent recognition of 
apoptotic cells.
The multiligand receptor CD36 is one of several recep-
tors implicated in mediating phagocyte recognition of apop-
totic cells during engulfment. Other receptors potentially 
involved in apoptotic cell clearance include SRB1, SRA, 
LOX-1, CD68, CD14, and the recently cloned protein with 
reported binding activity for PS-containing membranes, the 
PS receptor (PSR) (11). Numerous lines of evidence have 
supported a role for receptor-mediated recognition of PS on 
the surface of apoptotic cells. It is interesting to note that all 
of these receptors, aside from PSR, were originally described 
to bind oxLDL. Indeed, CD36 and other scavenger receptors 
are thought to recognize ligands in the apoptotic cell mem-
brane that mimic oxLDL structure (11). Consistent with this, 
the present studies demonstrated partial competition of apop-
totic cell phagocytosis by macrophages in the presence of ex-
cess oxPC-containing SUVs. Although many receptors have 
been implicated, similar to oxLDL recognition, little is known 
Figure 6.  Co-incubation with oxPS versus oxPC vesicles reveals a 
primary role for oxPS-CD36 interactions in macrophage phagocyto-
sis of apoptotic cells. (a) K562 cells transfected with plasmids express-
ing CD36,GFP (bicistronic) were cultured overnight and incubated with 
POPC vesicles containing 20 mol% oxidized PAPS (oxPS) labeled with the 
lipophilic dye Di-I at 4°C for 30–60 min in the presence or absence of a 
10-fold excess of either unlabeled oxPLPC (oxPC) or oxPS vesicles 
(20 mol% in POPC). After extensive washing to remove unbound vesicles, 
CD36 expression and oxPS binding (red fl  uorescence) were analyzed 
  simultaneously by two-color fl  ow cytometry. (b) oxPS vesicle binding is 
shown for the single CD36 expression level indicated by the dashed-line 
rectangle in panel a. Results represent the mean ± SD for three inde-
pendent experiments. (c) 106 UV-irradiated apoptotic HL60 cells were 
overlaid onto 105 CD36-expressing (WT) MPMs and incubated for 1 h at 
37°C, in the presence or absence of the indicated lipid-containing vesi-
cles (made in POPC at 20 mol%). After extensive washing, bound and 
ingested HL60 cells were revealed by in situ peroxidase (dimethylbenzi-
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regarding the precise nature of the ligands on apoptotic cell 
membranes that are recognized by phagocytes.
Although PS has traditionally been referred to as the “eat-me” 
signal for receptor-mediated phagocytosis of apoptotic cells, a 
role for PS oxidation in generating this signal has been less 
clear. The present studies strongly argue that virtually all of 
CD36-mediated PS recognition is via oxPS species. Indeed, 
PS commonly used in the literature likely contains substantial 
amounts of oxPS, particularly when methodologies used to 
prepare PS liposomes induce  oxidation, such as sonication 
and dialysis in the absence of both antioxidants and chelating 
agents for redox active transition metals (8, 9, 25, 29). More-
over, sources of PS used in published studies are typically 
  derived from brain or liver and contain large amounts of 
polyunsaturated fatty acid species susceptible to oxidation. 
Mass spectrometry analyses of multiple commercial sources 
of PS all showed readily measurable levels of oxPSCD36 (un-
published data). Further, in liposome binding studies with 
incorporation of low molar percent (10 mol%) PS derived 
from brain (without any prior HPLC reisolation to remove 
contaminant oxPS species), considerable binding to CD36 is 
readily observed in a dose-dependent manner. In contrast, 
incorporation of comparable levels of less oxidizable PS spe-
cies (e.g., POPS or 1,2-dipalmitoyl-sn-glycero-3-phospho-
serine) shows nominal background binding levels. It is thus 
our belief that oxPS may have accounted for observed CD36 
binding activity in many previously published studies (8, 9, 
25, 26, 29) demonstrating a role for CD36–PS interactions 
during phagocytosis of apoptotic cells.
A growing body of evidence indicates the involvement of 
oxidized phospholipids as pattern recognition ligands for 
scavenger receptors on phagocytic cells. Our current data 
strongly support this hypothesis, focusing attention on CD36 
and the sn-2 acyl moiety of oxPS, and to a lesser extent 
oxPC, as critical for apoptotic cell recognition. It is interest-
ing to note that Kagan et al. have suggested the importance 
of oxidized PS ligands in apoptotic cell membranes required 
for effi     cient phagocytosis and clearance by mouse macro-
phages (27). However, neither the specifi  c receptors involved 
nor the candidate ligands were identifi  ed. The range and 
complexity of the full spectra of oxPS species suggests that 
multiple potential ligands may be generated. Several oxPS 
species detected share the identical sn-2 oxidized fatty acids as 
observed in oxPCCD36 analogues (23, 24). That the indicated 
oxPS species (Table I and Fig. 9) are present in apoptotic 
membranes is strongly supported, however, by the extensive 
characterization of the fragmentation pattern of MS2 and 
MS3 daughter ions, as well as comparison with the known 
fragmentation pattern of the oxidized sn-2 fatty acids in syn-
thetic oxPC species. The MSn data thus provide strong cor-
roboration that the phosphoserine headgroup-containing 
structural analogues of the oxPCCD36  ligands are indeed 
formed during apoptosis.
Our phagocytosis competition assay and PS lipid membrane 
enrichment assay both indicate that CD36 is the predominant 
Figure 7.  WT MPMs phagocytose viable (nonapoptotic) HL60 
cells enriched with oxPS but not PS. 106 HL60 cells/ml were enriched 
with 2 mg of lipid vesicles in 1 ml PBS (either POPC carrier alone or carrier 
+ 16 mol% of either PAPS or oxidized PAPS) for 30 min at 37°C, as de-
scribed in Materials and methods. Cells were washed and stained with 
annexin V or overlaid onto MPMs. (a) Nonapoptotic cells were stained 
with FITC-labeled annexin V. Note that the addition of external carrier 
POPC failed to promote annexin V staining, whereas external incorpora-
tion of either PS or oxPS within carrier POPC similarly enhanced annexin 
V staining of cells. (b and c) Nonapoptotic cells labeled with external POPC 
carrier alone, or POPC + either PS or oxPS, and used in phagocytosis 
assay were overlaid onto either CD36 WT (b) or CD36-null (c) MPMs. 
*, P < 0.02 versus control.
Figure 8.  Common fragmentation pattern of PS molecular species 
during negative ion chemical ionization electrospray ionization mass 
spectrometry. Shown are common fragmentation pathways for PS mo-
lecular species under negative ion electrospray ionization mass spectrom-
etry conditions. The origins of multiple common and specifi  c ions for PS 
molecular species are illustrated. The neutral loss corresponding to the 
aziridine-2-carboxylic acid daughter accounts for the characteristic loss 
of 87.0 amu.JEM VOL. 203, November 27, 2006  2623
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receptor for oxPS on the surface of CD36 WT macrophages. 
Intriguingly, CD36-null macrophages phagocytose both PS 
liposomes and viable HL60 cells enriched with PS at the 
plasma membrane more effi   ciently than oxPS liposomes or 
oxPS-enriched cells. We can speculate that in the absence of 
the CD36 receptor, alternate receptors may be overexpressed 
as a compensatory adaptation and that these receptors bind 
PS with a higher affi   nity. We have examined the expression 
levels of SRA and PSR in WT and CD36 KO MPMs by both 
immunostaining and Western blot analyses and see no impor-
tant diff  erences at the protein level, suggesting that SRA and 
PSR are not the up-regulated receptor in the CD36 KO 
MPMs (unpublished data). Although a consensus on the mo-
lecular identity and characteristics of a macrophage PSR has 
been questioned by some (30, 31), we at present do not know 
the identity of the PS binding receptor that is up-regulated in 
the CD36 KO MPMs.
It is intriguing to consider that, similar to uptake of 
  oxLDL, recognition of common oxidation motifs by multiple 
phagocyte cell surface receptors has been exploited in such 
an evolutionarily conserved cellular process as apoptotic cell 
recognition and removal. Further understanding and charac-
terization of scavenger receptor–oxidized phospholipid 
  ligand interactions and downstream cellular consequences 
triggered by engagement of structurally specifi  c oxPC and 
oxPS ligands is of interest.
MATERIALS AND METHODS
Materials. Unless otherwise indicated, lipids were purchased from Avanti 
Polar Lipids, Inc. and were confi  rmed to be >98% pure by mass spectrome-
try analyses. In an eff  ort to remove trace levels of oxPS species present in 
even the best commercial PS sources, the oxidant-sensitive PS species PLPS 
and PAPS were purifi  ed by preparative HPLC and stored under argon atmo-
sphere within amber vials at −80°C. CellTracker Green 5-chloromethylfl  u-
orescein diacetate (CMFDA; Invitrogen) and Di-I were obtained from 
Invitrogen. All other reagents were purchased from either Sigma-Aldrich or 
Fisher Scientifi  c, unless otherwise specifi  ed. Anti–mouse CD36 antibody 
was made as described previously (32), anti-Fas clone CH-11 was obtained 
from Upstate Biotechnology, and anti–human CD36-phycoerythrin, anti-
phosphatidyl serine receptor (human), and annexin V–FITC apoptosis detec-
tion kits were from BD Biosciences.
Cell Culture. Human chronic myelogenous leukemia cells (K562), promy-
elocytic leukemia cells (HL60), human Jurkat T cells, and primary 
MPMs were cultured in RPMI 1640 supplemented with 10% fetal bovine 
serum and penicillin/streptomycin antibiotics. African green monkey 
kidney fi  broblasts (Cos-7) were cultured in DMEM supplemented with 10% 
fetal bovine serum and pen/strep antibiotics.
Construction of plasmids and transfections. Open reading frame 
  encoding WT CD36 protein was subcloned into pCGCG (33) bicistronic 
expression vector containing GFP under translational control of a picornavi-
rus (EMCV) IRES. This plasmid is referred to as CD36,GFP (bicistronic) in 
Fig. 2. Cells were transfected with 20 μg DNA in media made to 150 mM 
NaCl supplemented with 10 mM Hepes, pH 7.4, using an electroporator 
(Gene Pulser; Bio-Rad Laboratories) at 950 μF and 230 (K562) or 200 
(Cos-7) V. Time constants were typically in the range of 44–48 ms.
Vesicle preparation and modifi  cation. 2-mg/ml stock solutions of 
SUVs comprised of PLPS, PAPS, POPS, or POPC with varying mole 
  percents of specifi  c oxidized phospholipids were prepared in argon-sparged 
sodium phosphate buff   er by extrusion (11 times) through a 0.1-μm 
polycarbonate fi  lter using a Mini-Extruder set (Avanti Polar Lipids) at 37°C. 
For a typical experiment, the relatively nonoxidizable phospholipid POPC 
was used as carrier, and the specifi  ed PS species was incorporated as a minor 
component (20 mol% or less, as indicated in the fi  gures). For direct binding 
experiments, 1 mol% of Di-I was dried down together with the phospholipids   
indicated in the fi  gures and incorporated into lipid vesicles by extrusion. 
CD36 ligands were isolated from PAPS or PLPS vesicles after oxidation by 
exposure to 30 nm MPO, an H2O2-generating   system comprised of 100 
μM glucose and 100 ng/ml glucose oxidase, and 0.5 mM NaNO2 at 
37°C for 18 h. Reactions were stopped by the addition of 40 μM butyl-
ated hydroxytoluene and 300 nM catalase and stored under argon atmo-
sphere at −80°C until use in cell binding studies. oxLDL was used as a 
prototypic ligand for CD36. It was formed as   described by exposure of 
Figure 9.  Demonstration of oxidized PS species in apoptotic mem-
branes using negative ion LC/MS/MS. The presence of oxidized PAPS 
or PLPS species in lipid extracts of apoptotic cells was analyzed by HPLC 
with on-line negative ion electrospray ionization tandem mass spectrom-
etry. Separation was done on a reverse phase C18 column (2.1 × 250 mm, 
5μm) using methanol/water as mobile phase at a fl  ow rate of 0.2 ml/min 
with gradient and oxidized PLPS (a) and PAPS (b) molecular species identi-
fi  ed by their characteristic retention time and daughter ions specifi  c for 
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isolated human LDL to the MPO–H2O2–NO2
− system (34). Previous 
experiments have demonstrated that CD36 is the major receptor on 
MPMs that recognize LDL oxidized by this physiological method (17).
Flow cytometry and fl  uorescent microscopy analysis. Flow cytom-
etry studies were performed on a FACScan (Becton Dickenson). For 
binding studies, 2 × 105 cells in 200 μl (as indicated in the fi  gures) were 
incubated with 500 μg/ml Di-I–labeled liposomes at 4°C for 30 min to 
1 h. Although cells incubated with Di-I–labeled liposomes at 37°C for 2 h 
(binding and uptake) showed similar results, we only present the binding 
(4°C) data. After incubation, cells were pelleted, washed three times with 
PBS containing 0.1% BSA, and resuspended in 400 μl for immediate 
analysis. For fl  uorescent microscopy, cells were grown on glass coverslips 
and incubated with Di-I–labeled oxLDL or liposomes at 4°C for 30 min. 
After incubation, cells were fi  xed with 3.7% paraformaldehyde for 20 min 
and mounted on glass slides with VectaShield mounting media (Vector 
Laboratories). Fluo  rescent microscopy studies were performed on a mi-
croscope (DMR; Leica) and CCD camera (EX1; QImaging), and images 
were processed on Image-Pro software.
Phagocytosis assays. Suspension cells were rendered apoptotic after 254 nm 
UV irradiation for either 5 min (HL60) or 10 min (Jurkat). The cells were 
then cultured an additional 2–3 h before use. Apoptosis was also induced in 
Jurkat cells by incubating for 6 h at 37°C with 20 ng/ml anti-Fas antibody. 
Apoptosis was confi  rmed by multiple independent methods, including an-
nexin V–FITC staining (>50% annexin V positive), DNA laddering assay, and 
nuclear morphology. 106 apoptotic cells were then layered over a monolayer 
(105) of adherent cells (CD36- or vector-transfected Cos-7 cells or MPMs) 
cultured on glass coverslips and co-cultured in 200 μl DMEM (Cos-7) or 
RPMI 1640 (MPM) media for 1 h at 37°C. After incubation, unbound apop-
totic cells were removed by extensive washing with media and then with 
PBS. Bound or ingested HL60 cells were visualized by in situ peroxidase 
staining (for HL60 MPO) with dimethybenzidine, a peroxidase substrate 
(35). In brief, cells were incubated in 200 μl 0.1 M NaPO4, pH6.2, followed 
by addition of 20 μl 0.05% H2O2 and 20 μl 1.25 mg/ml dimethoxybenzi-
dine. Color development was stopped after 15–30 min by washing the cov-
erslip with PBS and mounting in Vectashield mounting media on a glass slide. 
Bound or ingested Jurkat cells were detected by their green fl  uorescence af-
ter labeling with CellTracker Green CMFDA (according to manufacturer’s 
  instructions) before UV irradiation. Ingested cells were counted using Image-
Pro software in at least four microscopic fi  elds (300 cells/fi  eld). The bound 
and ingested apoptotic cells (HL60 or Jurkat) and the adherent cells (Cos-7 
or MPM) were counted using   Image-Pro software, and the percent phagocy-
tosis was calculated by dividing the number of apoptotic cells ingested or 
bound by the total number of adherent phagocytizing cells in the monolayer 
(Cos-7 or MPM). For PS and oxPS competition experiments, 100 μl PS or 
oxPS vesicles (2 mg/ml) were mixed with 100 μl of control or apoptotic 
HL60 cells (106) and overlayed onto phagocytic cells (MPM or Cos-7) for 
1 h at 37°C. Subsequent processing and analysis of bound and ingested cells 
was done as described.
MPMs. CD36 KO mice backcrossed >6 generations on a C57BL/6 
  background, along with C57BL/6 parent colonies, were used for these 
  studies. Mice were injected intraperitoneally with 1 ml thioglycollate media 
(4% in H2O), and cells were harvested by peritoneal lavage with sterile PBS/
RPMI 1640 (1:1) at 4 d after injection to maximize CD36 surface expres-
sion. Approximately 105 cells were plated on sterile glass coverslips in 
  complete RPMI 1640 media. All animal studies were performed using 
  approved protocols from the Animal Research Committee of the Cleveland 
Clinic Foundation.
PS and oxPS enrichment of HL60 cell membranes. Cell membranes 
were enriched with PS or oxPS species by co-incubation of liposomes 
with cells using an adaptation of the methods described by Fadok et al. (29). 
In brief, lipid vesicles were extruded in 1 ml PBS at 2 mg/ml under inert 
(argon) atmosphere. 106 HL60 cells were pelleted and resuspended in a 1-ml 
suspension of 2 mg/ml lipid of the lipid vesicles indicated in the fi  gures 
and incubated for 30 min at 37°C. After incubation, cells were washed two 
times with PBS and stained with annexin V and propidium iodide according 
to manufacturer’s instructions (annexin V–FITC apoptosis detection kit; BD 
Biosciences), or overlayed onto 105 MPMs cultured on glass coverslips and 
further incubated in RPMI 1640 media for an additional 2 h, and used in the 
phagocytosis assay. 
Wound analysis. 2-mo-old background- and gender-matched WT 
(C57BLK6) and CD36 KO (backcrossed more than six generations) mice 
were anesthetized, and 6-mm punch biopsies were created on the lower left 
or right quadrant of the shaved dorsum. The wounds were left uncovered 
and monitored daily, and at the indicated timed points excised, fi  xed in 10% 
formalin, paraffi   n embedded, and sectioned at an 8-μm thickness. Apoptotic 
cells in paraffi   n-embedded sections were identifi  ed using a fl  uorescein DNA 
fragmentation detection kit (QIA39; Calbiochem). For each wound section, 
the number of fl  uorescent cells was counted in three to fi  ve random 
low-power fi  elds (20×).
Statistics. The results are presented as mean ± SE values from at least three 
independent experiments, and statistical analyses were performed by the 
paired Student’s t test.
Mass spectrometry. Lipids were initially extracted three times by the 
method of Bligh and Dyer (36). The combined extracts were rapidly dried 
under nitrogen and stored under an argon atmosphere at −80°C until analy-
sis within 24 h. Mass spectra were acquired in negative ion mode using an 
LCQ ion trap mass spectrometer (LCQ; Thermo Finnigan) coupled with an 
electrospray ionization source. Capillary temperature was set at 300°C, and 
spray voltage was set at 4 kV. The fl  uid was nebulized using nitrogen as the 
sheath gas fl  ow at 10 au, the auxiliary gas fl  ow at 5 au, and the sweeping gas 
fl  ow at 5 au. All data were collected using the data-  dependent MSn function. 
Full spectra were collected from m/z 100 to 1,200. Collision-induced disso-
ciation was performed in the collision cell using He as the collision gas. All 
data were analyzed with Finnigan Xcalibur 1.4. The sample was dissolved in 
a mixture of methanol and chloroform (4:1, vol/vol), and both were infused 
directly into the mass spectrometer through a syringe pump at 3 μl/min, as 
well as via HPLC interface after reverse phase separation. MSn data of each 
compound are tabulated in Table I. Oxidized PS mixtures were characterized 
after reverse phase HPLC both on the LCQ ion trap instrument as described 
and on a triple quadruple mass spectrometer (Quattro   Ultima; Micromass). 
Each sample preparation (in 90% methanol) was injected onto a reverse phase 
C18 HPLC column (2 × 150 mm, 5 μm; ODS; Phenomenex) at a fl  ow rate 
of 0.2 ml/min. oxPSes were resolved using a gradient from water containing 
0.2% ammonium to methanol containing 0.2% ammonium. The column was 
equilibrated with 50% methanol and held at this composition for 6 min after 
the injection. A linear gradient was then run from 50 to 100% methanol over 
10 min. The solvent composition was held at 100% methanol for 13 min. For 
analyses on the Quattro Ultima, the mass spectrometer was confi  gured with 
the capillary voltage at 3 kV, the cone voltage at 40 V, the source temperature 
at 120°C, and a desolvation temperature at 250°C. The fl  ow rate for the ni-
trogen in the cone and desolvation gas was 100 and 800 L/h, respectively. 
Collision-induced dissociation was obtained using argon gas. Analyses were 
performed using electrospray ionization in the negative-ion mode with mul-
tiple reaction monitoring of parent [M-H] and characteristic daughter ions 
[M-H-87]. The m/z of the individual transitions monitored is shown in 
Fig. 9. Because of the resolution of the mass spectrometer and the complexity 
of the sample, multiple interfering peaks were also detected in some traces. To 
distinguish the peaks of target compounds from the interfering peaks, online 
MS/MS spectra of expected m/z of postulated compounds were collected 
(unpublished data) and compared with the spectra obtained by LCQ. 
The peaks that failed to display characteristic sn-2 side chain ions in the MS/
MS spectra were identifi  ed as interference. Fragmentation patterns of native 
and oxPS species were confi  rmed to follow common pathways as previously 
reported by Pulfer and Murphy (28).JEM VOL. 203, November 27, 2006  2625
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